Revenue and Profitability in Line with Expectations
Q2 revenue $5.4B, EBITDA $826M, EBIT $603M; adjusted EPS $0.86 for the quarter (adjusted EPS up 7% in Q2 and up 14% for the first half versus prior year).
Free Cash Flow and Dividend
Free cash flow of $289M in Q2 (first half cash outflow $53M, in line with expectations); Board declared quarterly dividend of $0.65 per share, up year-over-year; reaffirmed full-year free cash flow guidance of $1.8B–$1.9B.
Synergy Capture Accelerating
Synergy benefits accelerated to $55M in Q2 and totaled $93M in the first half; management reaffirmed at least $260M of synergies for fiscal 2026 and $650M through fiscal 2028; procurement target $325M by 2028.
Core Portfolio Resilience
Core portfolio (~$20B) outperformed the combined company: core volumes down ~1.5% (≈100 bps better than total portfolio) and adjusted EBIT dollars up ~7% for the core (excluding synergies, earnings broadly flat vs prior year).
Segment Performance — Rigid and Flexible
Flexible packaging sales +23% constant currency (driven by acquisition); flexible adjusted EBIT +22% cc to $402M (comparable EBIT up ~1%). Rigid adjusted EBIT $228M; on a comparable constant currency basis excluding non-core, rigid adjusted EBIT up ~15% and adjusted EBIT margin excluding non-core improved ~200 bps to ~12%.
Balance Sheet and Capital Allocation
Adjusted leverage exiting Q2 was 3.6x with expectation to end the year ~3.1–3.2x; FY capex expected $850M–$900M; commitment to maintain investment-grade rating and modestly growing dividend; first-half capex $459M.
Commercial Wins and Growth Synergies
Annualized sales from wins linked to the Berry combination now exceed $100M toward a three-year target of $280M; example win supplying blister packaging and rigid containers for a major pharmaceutical GLP-1 therapy.
Integration and Operational Progress
Over 600 headcount reductions executed consistent with integration roadmap; ~20 site closures/restructures approved/announced; early realization of G&A, procurement and financial synergies.